Stocks · Healthcare · Biotechnology
Xilio Therapeutics, Inc. XLO
$9.01 +1.12% Close, Oct 2, 2026 · NASDAQ · Market cap $59.2M
Expensive vs sectorLow risk
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $64.1M, up 327.3% from a year earlier, slowing from 476.7% a quarter earlier.
- Operating margin widened to -48.9% from -377.4% a year earlier.
- The diluted share count rose 424.2% in a year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 5%
- Revenue growth accelerationBottom 3%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 46%
- Gross marginTop 6%
- Operating marginBottom 35%
- Accruals (lower is better)Bottom 4%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 35%
- Free-cash-flow yieldBottom 2%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 21%
- 6-month returnBottom 49%
- 1-year return vs S&P 500Bottom 27%
- Distance from 52-week highTop 44%
- Trend checklist (0–4)Top 20%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 15%
- Consecutive EPS beatsTop 25%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetTop 2%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 3%
- Maximum drawdown, 3 yearsBottom 32%
- Beta vs S&P 500 (lower is better)Top 5%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 476.7% | 327.3% | ↓ |
| Gross margin | -2.2% | 99.5% | ↑ |
| Operating margin | -377.4% | -48.9% | ↑ |
| FCF margin | -91.8% | -95.6% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 327.3% | 476.7% | ↓ | Top 5% |
| Gross margin | 99.5% | -2.2% | ↑ | Top 6% |
| Operating margin | -48.9% | -377.4% | ↑ | Bottom 35% |
| Net margin | -34.1% | -374.8% | ↑ | — |
| Free-cash-flow margin | -95.6% | -91.8% | ↓ | — |
| Return on invested capital | -25.8% | — | Bottom 46% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 25.1%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 12.3%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -130.54%
- Shareholder yield
- -130.54%
- Share count change, 1 year
- +424.2%
- Share count change, 3-year CAGR
- +114.7%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 12, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 3
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- -40.3%
- Average 2-day reaction, last 8
- -3.6%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $98.00
- Target vs current price
- +987.7%
- Analysts with a rating
- 3
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 13, 2026 | +44.1% | -0.4% | +4.0% | -1.3% | — |
| May 12, 2026 | +12.1% | +0.0% | +5.4% | +2.2% | +19.9% |
| Mar 23, 2026 | +49.4% | +0.0% | +5.9% | +7.5% | +5.0% |
| Nov 13, 2025 | -266.7% | -9.3% | +4.3% | -8.2% | -30.0% |
| Aug 14, 2025 | -100.0% | -1.7% | -7.2% | +2.1% | +16.3% |
| May 8, 2025 | -2190.9% | +8.0% | +27.5% | +1.8% | -1.4% |
| Mar 11, 2025 | +9.1% | -6.2% | -4.5% | -20.4% | -21.2% |
| Nov 7, 2024 | +12.0% | -19.4% | -22.6% | -18.6% | -46.3% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.33 | -$0.59 | +44.1% | $18.7M |
| May 12, 2026 | -$0.58 | -$0.66 | +12.1% | $12.7M |
| Mar 23, 2026 | -$0.85 | -$1.68 | +49.4% | $13.7M |
| Nov 13, 2025 | -$1.54 | -$0.42 | -266.7% | $19.1M |
| Aug 14, 2025 | -$2.24 | -$1.12 | -100.0% | $8.1M |
| May 8, 2025 | -$2.52 | -$0.11 | -2190.9% | $2.9M |
| Mar 11, 2025 | -$2.80 | -$3.08 | +9.1% | $1.7M |
| Nov 7, 2024 | -$3.08 | -$3.50 | +12.0% | $2.3M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| Free-cash-flow yield | -103.42% | — | — | Bottom 2% |
| Earnings yield | -18.20% | — | — | Bottom 35% |
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 49
- 50-day average slope (20 days)
- -0.2%
- 200-day average slope (20 days)
- -1.4%
- Distance from 50-day average
- -0.6%
- Distance from 200-day average
- +5.0%
- RSI (14)
- 50.0
- Relative volume
- 0.76×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 23.5%
- Volatility vs own 5-year history
- 0th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.21
- Correlation with S&P 500
- 0.04
- Current drawdown from 1-year high
- -24.3%
- Maximum drawdown, 3 years
- -80.0%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Nov 16, 2021 | Dec 20, 2023 | -98.0% | 526 days | Not yet recovered |
| Nov 2, 2021 | Nov 3, 2021 | -15.1% | 1 days | 1 days (Nov 4, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $59.2M
- EPS, diluted (TTM)
- -$1.64
- Revenue (TTM)
- $64.1M
- 52-week range
- $6.47 – $12.58
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $6.3M | $43.8M |
| Gross profit | -$1.5M | $0 | $0 | $6.3M | $42.2M |
| Operating income | -$75.0M | -$89.1M | -$79.1M | -$60.6M | -$42.0M |
| Net income | -$75.8M | -$88.2M | -$76.4M | -$58.2M | -$35.0M |
| EPS (diluted) | -$189.28 | -$45.08 | -$38.92 | -$15.26 | -$4.19 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.3M | $1.7M | $2.9M | $8.1M | $19.1M | $13.7M | $12.6M | $18.7M |
| Net income | -$14.0M | -$13.1M | -$13.3M | -$15.8M | -$16.3M | $10.4M | -$9.5M | -$6.4M |
| EPS (diluted) | -$3.08 | -$2.80 | -$2.52 | -$4.34 | -$1.54 | $0.81 | -$0.58 | -$0.33 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$80.8M | -$75.7M | -$68.6M | -$18.4M | -$5.0M |
| Capital expenditure | -$1.1M | -$1.9M | -$486,000 | -$36,000 | -$518,000 |
| Free cash flow | -$81.9M | -$77.6M | -$69.1M | -$18.4M | -$5.5M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $116.4M | $16,000 | $202,000 | $6.8M | $87.8M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $136.0M
- Total assets
- $154.3M
- Total liabilities
- $82.0M
- Total debt
- $6.3M
- Net debt
- -$129.7M
- Shareholders’ equity
- $72.3M
As of Jun 30, 2026 (filed Aug 12, 2026).
Short interest
- Shares sold short
- 412,963
- Days to cover
- 37.36
- Change vs previous report
- -1.3%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Mar 16, 2026
- 1-for-14